drugset / Trial / NCT02762643

DP-R213 Pharmacokinetics Study

NCT02762643

Phase 1 Completed 61 enrolled Alvogen Korea
RandomizedCrossoverOpen-labelTreatment

Summary

A randomized, open-label, crossover, Phase I clinical trial to compare the pharmacokinetics of DP-R213 (Raloxifenel and Cholecaliferol fixed dose combinations) in comparison to each component administered alone in healthy male volunteers.

Timeline

Start
2016-05
Primary completion
2016-07
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholecaliferol Unknown
Subject DP-R213 Unknown
Subject Raloxifene Other / unclassified

Indications

No indication recorded.